"Abbott has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the fastest available molecular point-of-care test for the detection of novel coronavirus (COVID-19), delivering positive results in as little as five minutes and negative results in 13 minutes", the company said in a press release.
According to Abbott, the particular advantage of its tests is their size – a 6.6-pound lightweight box with a size of a small toaster – which makes it possible to use them outside of hospitals in places like the physicians' office or urgent care clinics.
Last week, another US company, Cepheid, said its tests got FDA's emergency use authorisation. Its Xpert® Xpress SARS-CoV-2 use the rapid molecular diagnostic method to detect the coronavirus strain that causes COVID-19, vowing to deliver results in 45 minutes.
The number of confirmed COVID-19 cases in the United States surpassed 100,000 on Friday evening, according to the Johns Hopkins University real-time tracker.